Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

The contribution of particulate matter to respiratory allergy.

Sompornrattanaphan M, Thongngarm T, Ratanawatkul P, Wongsa C, Swigris JJ.

Asian Pac J Allergy Immunol. 2020 Mar;38(1):19-28. doi: 10.12932/AP-100619-0579. Review.

2.

Performance of pulmonary artery dimensions measured on high-resolution computed tomography scan for identifying pulmonary hypertension.

Ratanawatkul P, Oh A, Richards JC, Swigris JJ.

ERJ Open Res. 2020 Feb 10;6(1). pii: 00232-2019. doi: 10.1183/23120541.00232-2019. eCollection 2020 Jan.

3.

IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis.

Solomon JJ, Matson S, Kelmenson LB, Chung JH, Hobbs SB, Rosas IO, Dellaripa PF, Doyle TJ, Poli S, Esposito AJ, Visser A, Marin AI, Amigues I, Fernández Pérez ER, Brown KK, Mahler M, Heinz D, Cool C, Deane KD, Swigris JJ, Demoruelle MK.

Chest. 2019 Dec 23. pii: S0012-3692(19)34454-X. doi: 10.1016/j.chest.2019.12.005. [Epub ahead of print]

PMID:
31877269
4.

Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Amigues I, Ramadurai D, Swigris JJ.

Open Access Rheumatol. 2019 Oct 15;11:229-235. doi: 10.2147/OARRR.S166070. eCollection 2019.

5.

Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.

Chartrand S, Lee JS, Swigris JJ, Stanchev L, Fischer A.

Lung. 2019 Dec;197(6):709-713. doi: 10.1007/s00408-019-00276-7. Epub 2019 Oct 3.

PMID:
31583453
6.

Reliability and validity of Chinese version of a tool to assess the quality of life in idiopathic pulmonary fibrosis in patients with interstitial lung disease.

Pan RL, Swigris JJ, Zhao YW, Guo AM, Wu Q, Li SJ.

Int J Nurs Sci. 2018 Nov 21;6(1):38-42. doi: 10.1016/j.ijnss.2018.11.005. eCollection 2019 Jan 10.

7.

Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers.

Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, Swigris JJ.

Chron Respir Dis. 2019 Jan-Dec;16:1479973119858961. doi: 10.1177/1479973119858961.

8.

Interstitial Pneumonia with Autoimmune Features and Undifferentiated Connective Tissue Disease.

Chernau AK, Leone PM, Swigris JJ.

Semin Respir Crit Care Med. 2019 Apr;40(2):271-277. doi: 10.1055/s-0039-1684007. Epub 2019 May 28.

PMID:
31137065
9.

Reply to Hall et al.: Hypersensitivity Pneumonitis Mortality by Industry and Occupation.

Fernández Pérez ER, Sprunger D, Ratanawatkul P, Maier LA, Huie TJ, Swigris JJ, Solomon JJ, Mohning M, Keith RC, Brown KK.

Am J Respir Crit Care Med. 2019 Aug 15;200(4):518-519. doi: 10.1164/rccm.201904-0876LE. No abstract available.

10.

Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease.

Wijsenbeek MS, Holland AE, Swigris JJ, Renzoni EA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):152-159. doi: 10.1164/rccm.201903-0614PP. Review. No abstract available.

PMID:
31051080
11.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

12.

Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease.

Suzuki A, Kondoh Y, Swigris JJ, Matsuda T, Kimura T, Kataoka K, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y.

Respir Med. 2019 Apr;150:15-20. doi: 10.1016/j.rmed.2019.01.017. Epub 2019 Feb 1.

PMID:
30961943
13.

Increasing Hypersensitivity Pneumonitis-related Mortality in the United States from 1988 to 2016.

Fernández Pérez ER, Sprunger DB, Ratanawatkul P, Maier LA, Huie TJ, Swigris JJ, Solomon JJ, Mohning MP, Keith RC, Brown KK.

Am J Respir Crit Care Med. 2019 May 15;199(10):1284-1287. doi: 10.1164/rccm.201807-1258LE. No abstract available.

PMID:
30768910
14.

Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases.

Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, Thavarajah K, Tomic R, Inoue Y.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180075. doi: 10.1183/16000617.0075-2018. Print 2018 Dec 31. Review.

15.

Optimizing Home Oxygen Therapy. An Official American Thoracic Society Workshop Report.

Jacobs SS, Lederer DJ, Garvey CM, Hernandez C, Lindell KO, McLaughlin S, Schneidman AM, Casaburi R, Chang V, Cosgrove GP, Devitt L, Erickson KL, Ewart GW, Giordano SP, Harbaugh M, Kallstrom TJ, Kroner K, Krishnan JA, Lamberti JP, Porte P, Prieto-Centurion V, Sherman SE, Sullivan JL, Sward E, Swigris JJ, Upson DJ.

Ann Am Thorac Soc. 2018 Dec;15(12):1369-1381. doi: 10.1513/AnnalsATS.201809-627WS.

PMID:
30499721
16.

A New Tool to Capture Patients' Perceptions of the Effects of Lung Transplantation.

Swigris JJ.

Am J Respir Crit Care Med. 2019 Apr 15;199(8):941-943. doi: 10.1164/rccm.201810-2001ED. No abstract available.

17.

Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.

Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, Swigris JJ.

J Rheumatol. 2019 Apr;46(4):360-369. doi: 10.3899/jrheum.171315. Epub 2018 Nov 15. Erratum in: J Rheumatol. 2019 Feb;46(2):218.

18.

Towards a refined definition of combined pulmonary fibrosis and emphysema.

Swigris JJ.

Respirology. 2019 Jan;24(1):9-10. doi: 10.1111/resp.13426. Epub 2018 Oct 15. No abstract available.

19.

A Patient-Centered Approach to Care and Research in Chronic Disease.

Swigris JJ.

Am J Med Sci. 2019 Feb;357(2):85-86. doi: 10.1016/j.amjms.2018.08.008. Epub 2018 Aug 21. No abstract available.

PMID:
30278878
20.

Minimal Important Difference for Physical Activity and Validity of the International Physical Activity Questionnaire in Interstitial Lung Disease.

Hur SA, Guler SA, Khalil N, Camp PG, Guenette JA, Swigris JJ, Ryerson CJ.

Ann Am Thorac Soc. 2019 Jan;16(1):107-115. doi: 10.1513/AnnalsATS.201804-265OC.

PMID:
30211616
21.

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.

Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA.

Eur Respir J. 2018 Sep 17;52(3). pii: 1801384. doi: 10.1183/13993003.01384-2018. Print 2018 Sep.

22.

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.

Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW.

BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018.

23.

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.

Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD.

Respiration. 2018;96(6):514-524. doi: 10.1159/000490667. Epub 2018 Aug 16.

24.

Transitions and touchpoints in idiopathic pulmonary fibrosis.

Swigris JJ.

BMJ Open Respir Res. 2018 Jun 29;5(1):e000317. doi: 10.1136/bmjresp-2018-000317. eCollection 2018.

25.

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials.

Swigris JJ, Wilson H, Esser D, Conoscenti CS, Stansen W, Kline Leidy N, Brown KK.

BMJ Open Respir Res. 2018 May 18;5(1):e000278. doi: 10.1136/bmjresp-2018-000278. eCollection 2018.

26.

The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease.

Ramadurai D, Riordan M, Graney B, Churney T, Olson AL, Swigris JJ.

Respir Med. 2018 May;138:32-37. doi: 10.1016/j.rmed.2018.03.025. Epub 2018 Mar 26.

27.

Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign".

Zhan X, Koelsch T, Montner SM, Zhu A, Vij R, Swigris JJ, Chung JH.

J Thorac Imaging. 2018 Jul;33(4):266-270. doi: 10.1097/RTI.0000000000000328.

PMID:
29683868
28.

Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort.

Gopalakrishnan V, Jones AM, Julien-Williams P, Machado T, Danner RL, Swigris JJ, Paine R 3rd, Lozier JN, Moss J.

ERJ Open Res. 2018 Mar 20;4(1). pii: 00121-2017. doi: 10.1183/23120541.00121-2017. eCollection 2018 Jan.

29.

Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease.

Suzuki A, Kondoh Y, Swigris JJ, Ando M, Kimura T, Kataoka K, Yamano Y, Furukawa T, Numata M, Sakamoto K, Hasegawa Y.

Respirology. 2018 Mar 25. doi: 10.1111/resp.13293. [Epub ahead of print]

PMID:
29575410
30.

Understanding the informational needs of patients with IPF and their caregivers: 'You get diagnosed, and you ask this question right away, what does this mean?'

Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, Swigris JJ.

BMJ Open Qual. 2018 Jan 30;7(1):e000207. doi: 10.1136/bmjoq-2017-000207. eCollection 2018.

31.

Physical activity and activity space in patients with pulmonary fibrosis not prescribed supplemental oxygen.

Root ED, Graney B, Baird S, Churney T, Fier K, Korn M, McCormic M, Sprunger D, Vierzba T, Wamboldt FS, Swigris JJ.

BMC Pulm Med. 2017 Nov 23;17(1):154. doi: 10.1186/s12890-017-0495-2.

32.

Tracking dyspnea up to supplemental oxygen prescription among patients with pulmonary fibrosis.

Olson AL, Graney B, Baird S, Churney T, Fier K, Korn M, McCormick M, Sprunger D, Vierzba T, Wamboldt FS, Swigris JJ.

BMC Pulm Med. 2017 Nov 22;17(1):152. doi: 10.1186/s12890-017-0497-0.

33.

All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.

Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K.

J Rheumatol. 2018 Feb;45(2):235-241. doi: 10.3899/jrheum.170307. Epub 2017 Nov 15.

PMID:
29142033
34.

Idiopathic pulmonary fibrosis.

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU.

Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. Review.

PMID:
29052582
35.

Looking ahead and behind at supplemental oxygen: A qualitative study of patients with pulmonary fibrosis.

Graney BA, Wamboldt FS, Baird S, Churney T, Fier K, Korn M, McCormick M, Vierzba T, Swigris JJ.

Heart Lung. 2017 Sep - Oct;46(5):387-393. doi: 10.1016/j.hrtlng.2017.07.001. Epub 2017 Jul 31.

PMID:
28774655
36.

Informal caregivers experience of supplemental oxygen in pulmonary fibrosis.

Graney BA, Wamboldt FS, Baird S, Churney T, Fier K, Korn M, McCormick M, Vierzba T, Swigris JJ.

Health Qual Life Outcomes. 2017 Jul 1;15(1):133. doi: 10.1186/s12955-017-0710-0.

37.

Supplemental Oxygen for Patients with Interstitial Lung Disease: Managing Expectations.

Swigris JJ.

Ann Am Thorac Soc. 2017 Jun;14(6):831-832. doi: 10.1513/AnnalsATS.201703-236ED. No abstract available.

PMID:
28570155
38.

Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.

Natalini JG, Swigris JJ, Morisset J, Elicker BM, Jones KD, Fischer A, Collard HR, Lee JS.

Respir Med. 2017 Jun;127:1-6. doi: 10.1016/j.rmed.2017.04.002. Epub 2017 Apr 5.

39.

High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival.

Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, Keith RC, Janssen WJ, Goldstein BL, Lynch DA, Brown KK, Swigris JJ, Solomon JJ.

Respir Med. 2017 May;126:100-104. doi: 10.1016/j.rmed.2017.03.027. Epub 2017 Mar 30.

40.

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis.

Swigris JJ, Esser D, Wilson H, Conoscenti CS, Schmidt H, Stansen W, Leidy NK, Brown KK.

Eur Respir J. 2017 Jan 18;49(1). pii: 1601788. doi: 10.1183/13993003.01788-2016. Print 2017 Jan.

41.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
42.

Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.

Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A.

Respir Med. 2016 Oct;119:150-154. doi: 10.1016/j.rmed.2016.09.002. Epub 2016 Sep 3.

43.

Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Cao M, Swigris JJ, Wang X, Cao M, Qiu Y, Huang M, Xiao Y, Cai H.

Mediators Inflamm. 2016;2016:6940480. doi: 10.1155/2016/6940480. Epub 2016 Aug 25.

44.

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.

Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ.

Eur Respir J. 2016 Sep;48(3):843-51. doi: 10.1183/13993003.01966-2015. Epub 2016 Jul 28.

45.

Idiopathic Pulmonary Fibrosis on the Internet. Let's Calm the Sea of (Mis)information.

Lederer DJ, Swigris JJ.

Am J Respir Crit Care Med. 2016 Jul 15;194(2):134-6. doi: 10.1164/rccm.201601-0190ED. No abstract available.

PMID:
27420357
46.

Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis.

Olson AL, Brown KK, Swigris JJ.

Patient Relat Outcome Meas. 2016 May 17;7:29-35. doi: 10.2147/PROM.S74857. eCollection 2016. Review.

47.

What's it like to live with idiopathic pulmonary fibrosis? Ask the experts.

Russell AM, Swigris JJ.

Eur Respir J. 2016 May;47(5):1324-6. doi: 10.1183/13993003.00109-2016. No abstract available.

48.

Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease.

Mannina A, Chung JH, Swigris JJ, Solomon JJ, Huie TJ, Yunt ZX, Truong TQ, Brown KK, Achcar RD, Olson AL, Cox CW, Kligerman SJ, Curran-Everett D, Fernández Pérez ER.

Ann Am Thorac Soc. 2016 Jul;13(7):1042-9. doi: 10.1513/AnnalsATS.201511-728OC.

PMID:
27064856
49.

The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation.

Morisset J, Dubé BP, Garvey C, Bourbeau J, Collard HR, Swigris JJ, Lee JS.

Ann Am Thorac Soc. 2016 Jul;13(7):1026-33. doi: 10.1513/AnnalsATS.201512-836OC.

50.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU.

Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.

Supplemental Content

Loading ...
Support Center